Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radiocaine
- Development stage
- Unknown
- Lead developer
- Lutroo Imaging
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Radiocaine is a first-in-class PET radiotracer developed by Lutroo Imaging for the visualization and quantification of pain. It consists of a fluorine-18-labeled small molecule designed to bind specifically to voltage-gated sodium channels, which are upregulated in peripheral nerves during various painful conditions, including neuropathic, inflammatory, and cancer-related pain. By targeting these channels, Radiocaine serves as an imaging biomarker to localize pain sources, such as in lower back pain and neuropathic pain disorders. It received FDA Fast Track Designation in July 2025 and is currently undergoing Phase 1 clinical evaluation for safety, biodistribution, and radiation dosimetry.
- Brand names
- Radiocaine
- Other names
- Fluorine-18-labeled radiocaineFluorine18-labeled radiocaineFluorine 18-labeled radiocainelidocaine-Lutroo Imaging LLC-pain
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on Radiocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Radiocaine.